Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1471014
Reference Type
Journal Article
Title
Pregnancy outcome following gestational exposure to terbinafine: a prospective comparative study
Author(s)
Sarkar, MS; Rowland, K; Koren, G
Year
2003
Is Peer Reviewed?
Yes
Journal
Birth Defects Research, Part A: Clinical and Molecular Teratology
ISSN:
1542-0752
EISSN:
1542-0760
Report Number
DART/TER/3001195
Volume
67
Issue
5
Language
eng
Abstract
Terbinafine (Lamisil and Ntilde;) is a synthetic allylamine that is available as both an oral and topical antifungal. It is most commonly prescribed for the treatment of fungal infections of the toenail, fingernail (onchomycosis) and various tineal skin infections. Animal studies on pregnancy exposure revealed no evidence of harm to the fetus. To date, there are currently no well-controlled human studies that assess the safety of terbinafine use in pregnancy. Since August 1996, the manufacturer (Novartis) received a total of 55 spontaneous reports of oral use in pregnant patients. Out of the known outcomes, there were 26 live births, 8 SA's, 6 TA's, 2 congenital abnormalities and 1 neonatal death due to complications in a premature infant. The objective of this study is to evaluate the risk for major malformations and other adverse fetal effects following in utero exposure to terbinafine. Pregnant women who contacted Motherisk inquiring about terbinafine exposures were followed up. The exposed women were compared with 2 groups of women: 1) disease-matched using non-teratogenic antifungals for similar conditions and 2) exposed to non-teratogens. To date, we have completed follow-ups of 54 women gestationally exposed to terbinafine, of these, 26 were exposed to the oral form and 23 to topical. Of the 54 women in this cohort, 24 (45%) were exposed during the first trimester, while the mean duration of exposure to terbinafine was 32 +/- 9.0 days. Pregnancy outcome for exposed group included 50 (92.6%) live births, 3 (5.5%) SA's and 1 (1.9%) TA. One major malformation was noted in among the live births. This is an ongoing study, however, data collected thus far appears to suggest no increased risk for major malformations above baseline risk of 1-3%.
Tags
IRIS
•
Naphthalene
Previous HERO references
Database Searches
Toxline
Combined data set
Data set for title/abstract screening
Excluded - PECO criteria not met (TIAB)
Other
•
Naphthalene (2021 Evidence mapping publication)
Previous HERO references
Database Searches
Toxline
Combined data set
Data set for title/abstract screening
Excluded – PECO criteria not met
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity